Literature DB >> 19667927

Liver transplantation for cholangiocarcinoma.

Jason J Schwartz1, William R Hutson, Timothy J Gayowski, John B Sorensen.   

Abstract

Liver transplantation for cholangiocarcinoma (CCA) remains a controversial subject. More than 15 years after, a novel protocol combining neoadjuvant chemoradiation and orthotopic liver transplantation was first used in patients with unresectable hilar CCAs, these methods have yet to reach broad application. Results have confirmed that this approach leads to significantly lower recurrence rates and higher long-term survival rates than other existing treatment modalities. Despite this, protocols to treat patients with CCA are not widespread, and are available at only a handful of transplant programs. At these centers, treatment success may ultimately hinge on regional model for end-stage liver disease scores and waiting time for transplant. While acknowledging these factors as well as a severe organ shortage, it is important that the transplant community not overlook a potentially effective form of therapy for a previously untreatable disease.

Entities:  

Mesh:

Year:  2009        PMID: 19667927     DOI: 10.1097/TP.0b013e3181adc9e5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Recurrent Cholangiocarcinoma Presenting as Sister Mary Joseph Nodule After Liver Transplantation.

Authors:  Vijayadershan Muppidi; Sreenath Meegada; James D Eason; Satheesh P Nair; Rajanshu Verma
Journal:  Cureus       Date:  2020-11-24

2.  Issues in surgery for hilar cholangiocarcinoma.

Authors:  Sudeep R Shah
Journal:  Indian J Surg       Date:  2011-11-29       Impact factor: 0.656

3.  Surgical strategy for bile duct cancer: Advances and current limitations.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Daijo Hashimoto
Journal:  World J Clin Oncol       Date:  2011-02-10

4.  Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report.

Authors:  Waleed Al Hamoudi; Hatem Khalaf; Naglaa Allam; Mohammed Al Sebayel
Journal:  Hepat Mon       Date:  2012-10-28       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.